Liliana G Groppa

Prof. Liliana G Groppa


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2025 in Microbial Cell
Verified
Journal Article
Open access
ALAndrei Lobiuc
Andrei Lobiuc
LGLiliana G Groppa
Liliana G Groppa
LCLia Chislari
Lia Chislari
EREugeniu Russu
Eugeniu Russu
MHMarinela Homitchi
Marinela Homitchi
MCMihai Covasa
Mihai Covasa
Ankylosing spondylitis (AS) is a chronic inflammatory disease with complex pathogenesis influenced by genetic, immunological and environmental factors. Recent evidence suggests that gut microbiota significantly contributes to AS etiopathogenesis. Dysbiosis and altered immune responses in the gut potentially trigger or exacerbate the disease through intestinal barrier disruption, alteration of the IL-23/17 axis and metabolite production. This review explores the growing role of gut microbiota in AS and its potential to reshape targeted treatment strategies and facilitate development of adjunct therapies to address disease onset and progression. AS is a multifactorial disease in which gut dysbiosis plays a significant role influencing immune regulation notably through the IL-23/17 pathway. Alterations in gut microbiota composition and its metabolites contribute to systemic inflammation, reinforcing a self-perpetuating feedback loop between gut and spinal inflammation that drives disease progression. Emerging evidence has linked microbial mechanisms to HLA-B27 misfolding promoting endoplasmic reticulum stress and triggering molecular mimicry through gut microbial-associated molecular patterns further contributing to AS pathogenesis. Given the crucial role of gut microbiota in AS, targeting microbiota imbalances presents a promising avenue for novel therapeutic strategies. Although it remains unclear whether gut inflammation and microbial changes precedes AS onset, current evidence suggests an ongoing cycle of autoimmune inflammation involving both the gut and joints. Further research, particularly longitudinal studies, are needed to better understand the gut-joint axis and its potential therapeutic implications in AS management.

31 October 2023 in Folia Medica
Verified
Journal Article
Open access
PDF file
LRLarisa Andrei Rotaru
Larisa Andrei Rotaru
LGLiliana G Groppa
Liliana G Groppa
RERussu Eugeniu
Russu Eugeniu
CLChislari Lia
Chislari Lia
CCCătălin Codreanu
Cătălin Codreanu
CCCornelia Cornea
Cornelia Cornea
Introduction: Metabolic disorders are a public health issue because of the complications they cause, but they are also a major risk factor for the onset of gout. Aim: The current study set out to demonstrate clinically how the clinical-paraclinical evaluation methodology had advanced as well as to assess comorbidity in gout patients using diabetes mellitus (DM). We also wanted to examine the pancreatic dysfunction in gout patients of different ages (by assessing the glucose and glycolated Hb analyses). Materials and methods: Two hundred gout patients (mean age, men 60±8.0 years, women 63±9.0 years) were included in a descriptive, cross-sectional study. The diagnosis of gout was made according to the classification criteria for gout according to ACR and EULAR 2015. The raw data were analyzed using SPSS v. 26.0. Results: In the study, type 2 diabetes mellitus (DM2) was encountered with a comparable frequency among both middle-aged and elderly patients (33.8% and 41.8%, respectively, p=0.26). In only 15% of cases, DM2 preceded the development of gout (in 3% with the beginning and 12% with late onset), while the developmental age of the DM2 prior to gout was comparable (50.9±2.8 years in age group 1 and 55.1±6.9 years in age group 2). We found that elderly people experience gout much more frequently (up to 41%) when DM2 is present. However, DM2 is not considered a predictor of gout. Conclusions: In gout patients under the age of 59 inclusive, the mean age at diabetes onset is significantly lower than the age (37.49.6 years) at which diabetes develops in the general population. Early onset of diabetes is associated with early development of gout.

3 February 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
EDElena Deseatnicova
Elena Deseatnicova
ECEugenia Covaliov
Eugenia Covaliov
ODOlga Deseatnicova
Olga Deseatnicova
Rodica SiminiucRodica Siminiuc
Rodica Siminiuc
ERElena Rezus
Elena Rezus
LGLiliana G Groppa
Liliana G Groppa
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial joint inflammation and different system involvement that results in considerable physical and psychological symptoms. This narrative review investigates the impacts of nutritional diet therapy on RA symptoms, highlighting recent scientific findings in terms of how different dietary components may modulate inflammation and disease activity. Treatment of RA includes conventional and biological disease-modifying antirheumatic drugs (DMARDs) and symptomatic response modifiers, like corticosteroids and non-steroidal antirheumatic drugs (NSAIDS). However, nutritional interventions are becoming more and more popular due to their ability to alter inflammation. The review also focuses on macronutrients such as proteins and fats, stressing the usefulness of omega-3 fat acids/monounsaturated fat acids but warning against high intake of processed carbohydrates/sugars. Besides that, it explores the effects of micronutrients and bioactive compounds like polyphenols which may minimize RA symptoms and result in better disease control together with vitamin D or probiotics. This study highlights that incorporating anti-inflammatory foods can benefit the health and well-being of RA patients. Dietary modification may serve as a supportive approach alongside conventional treatments, helping patients improve both physical and mental aspects of their condition and achieve a better quality of life.

1 June 2025 in Moldovan Journal of Health Sciences
Verified
Journal Article
Closed access
RERussu Eugeniu
Russu Eugeniu
LGLiliana G Groppa
Liliana G Groppa
CLChislari Lia
Chislari Lia
MSMarius Semionov
Marius Semionov
ILIosif Leanca
Iosif Leanca
CNChiril Nartea
Chiril Nartea
Introduction. Neuropsychiatric lupus erythematosus is still a disease with a very challenging diagnostic process, lacking high specificity and sensitivity assays. Autoantibodies can change this perspective, and because of their pathogenetic involvement, can become a very powerful tool for early detection and disease activity tracking. However, their biomarker potential still needs further evaluation. In this study, we focused on the pathogenetic mechanisms of neuropsychiatric lupus erythematosus and the involvement of brain-specific and systemic autoantibodies in the development of neuropsychiatric manifestations. Material and methods. Medical articles addressing the correlation of autoantibodies concentrations in serum and cerebrospinal fluid and their potential pathogenetic mechanism, were reviewed. More than 100 articles were identified from databases such as PubMed, ScienceDirect, Frontiers, and Wiley, using keywords such as "neuropsychiatric lupus erythematosus", "autoantibodies", "pathogenesis", "biomarker" and "neuropsychiatric manifestations". From these, 47 articles were selected for the current review. Results. Autoantibodies truly are indeed a tool in the diagnostic process of neuropsychiatric lupus erythematosus, and many researchers have obtained statistically valid correlations between their presence and specific neuropsychiatric manifestations. Variations in their concentration not only reflect the disease activity but also the fact that they are involved in its development through interactions with neuronal and vascular targets. Besides autoimmunity, brain-blood barrier dysfunction is also another key part of the pathogenetic mechanism, with markers of this injury also being useful in the diagnostic methodology. With future research, specific combinations of these markers can be linked to distinct clinical manifestations by creating multi-biomarker panels, a robust framework for diagnosing neuropsychiatric lupus erythematosus. Conclusions. Neuropsychiatric lupus erythematosus remains a condition that highly challenging to diagnose and manage due to the heterogeneity of symptoms and the lack of standardized diagnostic tools. Autoantibodies, along with other markers of vascular and inflammatory injury can aid specialists in dealing with this disease, but further research is needed to validate these biomarkers in diverse patient populations and to standardize assays for clinical application to improve the early detection and management of NPSLE, ultimately enhancing patient outcomes and quality of life.

1 October 2022 in Moldovan Journal of Health Sciences
Verified
Journal Article
Closed access
LRLarisa Andrei Rotaru
Larisa Andrei Rotaru
LGLiliana G Groppa
Liliana G Groppa
SPSerghei Popa
Serghei Popa
TNTamilla Nurseitova
Tamilla Nurseitova
CCCornelia Cornea
Cornelia Cornea
Introduction. The incidence and prevalence of gout have increased worldwide in recent decades. Scientists at the Rochester Epidemiology Project (MN, USA) have seen a two-fold increase in the incidence of primary gout (patients without diuretic exposure) over a 20-year period, which ended in 1996. The increase of incidence may be related due to the difficulty and often unsatisfactory treatment options. The aim of the study was to systematize the recommendations on dietary treatment, and medication for patients with gout. Materials and methods. An analytical, qualitative, and secondary study was performed in the form of a synthesis article. 115 sources were identified and analyzed; from this list, 44 sources were selected according to the impact score during the publication period and according to the level of recommendations. Results. 44 articles were included. Most studies were small, retrospective analyses performed in single centers, with concerns for bias. Eleven studies (including five randomized controlled trials) reported improved patient outcomes following pharmacological interventions with known efficacy in gout, including allopurinol, prednisolone, NSAIDs and anakinra. Eight studies reported improved outcomes associated with non-pharmacological interventions: inpatient rheumatology consultation and a hospital gout management protocol. No studies to date have prospectively evaluated strategies designed to prevent re-admissions of patients hospitalized for gout flares. Conclusions. Urate crystals is completely soluble when we can lower the serum level of uric acid to normal values, but this often requires long-term treatment. The early onset of rehabilitation of affected joints helps to reduce the articular inflammatory process, the pain syndrome and it delays the progression of the underlying pathology while improving the quality of life in patients with gout. Further research is needed to enable healthcare providers to individualize and optimize gout treatment strategies, ensuring that patients with gout receive effective, safe, and high-quality care.

1 April 2024 in Moldovan Journal of Health Sciences
Verified
Journal Article
Closed access
TRTatiana Razlog
Tatiana Razlog
RERussu Eugeniu
Russu Eugeniu
ZAZinaida Alexa
Zinaida Alexa
ECEmil Ceban
Emil Ceban
CGCostina Groza
Costina Groza
LGLiliana G Groppa
Liliana G Groppa
Introduction. COVID-19 was initially considered a predominantly respiratory infection, with mortality associated with progression of respiratory failure, but currently is recognized as a multisystem disease with a wide range of manifestations. One of the most common complications of COVID-19 is acute kidney injury (AKI), which predominantly evolved to chronic kidney disease (CKD). The objective of the study was to investigate the types of acute kidney injury and their prognostic value in hospitalized patients with COVID-19 with evolution to chronic kidney disease. Material and methods. The study utilized a comprehensive database of patients admitted to general department of COVID-19 at Timofei Moșneaga Republican Clinical Hospital from 2020 to 2022 years (in total 1000 patients). The first part of the study was a retrospective study, focusing on patients with confirmed COVID-19 and lung injury was diagnosed by computer tomography. The second part was a prospective study assessing the prognostic value of inflammatory markers, renal functional status and kidney injury. Results. AKI occurs in 29.6% of patients with COVID-19. The risk of AKI and CKD is higher in patients with more comorbidities, a more severe course of disease, elevated levels of ASAT/ALAT > 1.6 and hematuria at admission, which significantly increases the risk of progression to CKD. Patients with a history of CKD, and who had ASAT > 40 U/L, ASAT/ALAT > 1.6 and hematuria, experience the onset of AKI before hospitalization. Independent negative predictors of hospital-developed AKI include hypertension, Charlson Comorbidity Index > 4 points, respiratory failure, ASAT/ALAT > 1.6, D-dimers > 250 ng/ml, and hematuria. Hospital mortality in patients with COVID-19 was 20.8%, compared to 8.5% in patients without AKI, and this rate increased to 50% when AKI developed (p < 0.001). Conclusions. Patients who developed AKI during admission had a higher incidence of negative outcomes compared to those with AKI prior to admission. Independent predictors of in-hospital mortality in COVID-19 patients were increased serum CRP. Death in hospitalized patients with COVID-19 and AKI was independently associated with factors such as age > 75 years, history of CKD, admission to Intensive Care Unit, leukocytosis, and ASAT/ALAT > 1.6.